Ing Groep Nv Vertex Pharmaceuticals Inc Transaction History

Ing Groep Nv

$16.5 Billion
Q3 2024

A detailed history of Ing Groep Nv transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Ing Groep Nv holds 53,538 shares of VRTX stock, worth $21.9 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares

53,538

Previous 66,125 19.04%

Holding current value

$21.9 Million

Previous $31 Million 19.67%

% of portfolio

0.15%

Previous 0.19%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	SELL	$460.0 - $505.78 $5.79 Million - $6.37 Million	-12,587 Reduced 19.04%	53,538 $24.9 Million
Q2 2024 Aug 13, 2024	SELL	$392.81 - $485.53 $4.29 Million - $5.3 Million	-10,918 Reduced 14.17%	66,125 $31 Million
Q1 2024 May 10, 2024	BUY	$407.69 - $446.08 $792,957 - $867,625	1,945 Added 2.59%	77,043 $32.2 Million
Q4 2023 Feb 08, 2024	SELL	$343.0 - $410.68 $3.45 Million - $4.13 Million	-10,060 Reduced 11.81%	75,098 $30.6 Million
Q3 2023 Oct 27, 2023	BUY	$338.18 - $362.46 $2.28 Million - $2.44 Million	6,745 Added 8.6%	85,158 $29.6 Million
Q2 2023 Aug 07, 2023	BUY	$314.42 - $351.91 $10.7 Million - $12 Million	34,115 Added 77.01%	78,413 $27.6 Million
Q1 2023 May 09, 2023	BUY	$283.23 - $323.1 $12.5 Million - $14.3 Million	44,298 New	44,298 $14 Million
Q3 2022 Nov 14, 2022	BUY	$273.83 - $305.53 $836,824 - $933,699	3,056 Added 5.36%	60,025 $17.4 Million
Q2 2022 Aug 08, 2022	BUY	$234.96 - $292.55 $10.8 Million - $13.4 Million	45,788 Added 409.52%	56,969 $16.1 Million
Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $7.26 Million - $8.56 Million	-32,806 Reduced 74.58%	11,181 $2.92 Million
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $3.12 Million - $3.94 Million	17,641 Added 66.96%	43,987 $9.66 Million
Q3 2021 Nov 02, 2021	BUY	$181.39 - $202.99 $94,322 - $105,554	520 Added 2.01%	26,346 $4.78 Million
Q2 2021 Aug 13, 2021	BUY	$187.49 - $221.1 $1.62 Million - $1.9 Million	8,614 Added 50.05%	25,826 $5.21 Million
Q1 2021 May 12, 2021	SELL	$207.02 - $241.31 $7,452 - $8,687	-36 Reduced 0.21%	17,212 $3.7 Million
Q4 2020 Feb 11, 2021	BUY	$207.01 - $276.09 $2.38 Million - $3.17 Million	11,483 Added 199.18%	17,248 $4.08 Million
Q3 2020 Nov 12, 2020	BUY	$255.65 - $303.1 $913,181 - $1.08 Million	3,572 Added 162.88%	5,765 $1.57 Million
Q2 2020 Aug 13, 2020	SELL	$225.48 - $295.8 $2.37 Million - $3.11 Million	-10,507 Reduced 82.73%	2,193 $637,000
Q1 2020 May 06, 2020	BUY	$199.77 - $247.81 $2.21 Million - $2.74 Million	11,062 Added 675.34%	12,700 $3.02 Million
Q4 2019 Feb 10, 2020	SELL	$166.71 - $223.91 $2.4 Million - $3.23 Million	-14,405 Reduced 89.79%	1,638 $359,000
Q3 2019 Nov 08, 2019	SELL	$166.23 - $187.09 $10 Million - $11.3 Million	-60,256 Reduced 78.97%	16,043 $2.72 Million
Q2 2019 Aug 12, 2019	BUY	$164.61 - $190.37 $71,440 - $82,620	434 Added 0.57%	76,299 $14 Million
Q1 2019 May 13, 2019	BUY	$163.73 - $194.7 $1.46 Million - $1.74 Million	8,916 Added 13.32%	75,865 $14 Million
Q4 2018 Feb 13, 2019	BUY	$151.91 - $192.21 $6.45 Million - $8.17 Million	42,491 Added 173.73%	66,949 $11.1 Million
Q3 2018 Nov 06, 2018	SELL	$167.73 - $192.74 $1.81 Million - $2.08 Million	-10,793 Reduced 30.62%	24,458 $4.71 Million
Q2 2018 Aug 10, 2018	SELL	$145.72 - $169.96 $1.25 Million - $1.46 Million	-8,585 Reduced 19.58%	35,251 $5.99 Million
Q1 2018 May 07, 2018	SELL	$151.6 - $177.13 $2.05 Million - $2.4 Million	-13,544 Reduced 23.6%	43,836 $7.14 Million
Q4 2017 Feb 06, 2018	BUY	$137.28 - $155.55 $1.58 Million - $1.79 Million	11,506 Added 25.08%	57,380 $8.6 Million
Q3 2017 Nov 08, 2017	BUY	$148.13 - $162.24 $6.8 Million - $7.44 Million	45,874	45,874 $6.98 Million

Others Institutions Holding VRTX

# of Institutions

1,724

Shares Held

221M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $105B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ing Groep Nv, based on Form 13F filings with the SEC.

News

Stay updated on Ing Groep Nv with notifications on news.

Account